- 23 March 2026: IHB's new research facility (Building 92) was inaugurated in Basel.
- CHF 1.4 billion is being invested in the Basel & Kaiseraugst site development.
- Building 92 accommodates up to 250 researchers and supports organoids, organ-on-chip and in silico human model systems.
- Roche invests ~CHF 3.5 billion in research annually and has invested around CHF 41 billion in Swiss R&D and site development since 2016.
Inauguration
On 23 March 2026 Roche opened the Institute of Human Biology's new research facility, Building 92 in Basel; Federal Councillor Elisabeth Baume-Schneider attended the official ceremony.
Research focus
IHB, founded in 2023, develops next-generation human model systems—advanced tissue cultures, organoids, organoids-on-chips and in silico modelling—combining human disease biology, computational biology and translational bioengineering to improve prediction of therapeutic effects.
Facility and operations
Building 92 houses up to 250 researchers and includes modular laboratories designed for sustainable growth and interdisciplinary exchange to bridge fundamental and industry sciences.
Investments and scale
Roche is investing CHF 1.4 billion in the Basel & Kaiseraugst site development; the company reports annual research expenditure of about CHF 3.5 billion and cites total Swiss R&D and site investments of roughly CHF 41 billion since 2016 (2016–2025).
